European Commission Approves Johnson & Johnson's Subcutaneous DARZALEX (daratumumab)-Based Quadruplet Regimen for the Treatment of Patients With Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
April 08, 2025
April 08, 2025
NEW BRUNSWICK, New Jersey, April 8 -- Janssen-Cilag International NV, a subsidiary of Johnson and Johnson, issued the following news release:
* * *
European Commission approves Johnson & Johnson's subcutaneous DARZALEX (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myelo . . .
* * *
European Commission approves Johnson & Johnson's subcutaneous DARZALEX (daratumumab)-based quadruplet regimen for the treatment of patients with newly diagnosed multiple myeloma, regardless of transplant eligibility
Approval cements daratumumab as a foundational therapy in newly diagnosed multiple myelo . . .